Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 2/20 | 0.46 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.40 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6975692 | 1.00 | AGTR2 (0.46) | AGTR2NR1D1POLBABHD6DAGLA | |
| SCHEMBL22555190 | 1.00 | AGTR2 (0.46) | AGTR2NR1D1POLBABHD6DAGLA | |
| SCHEMBL4294638 | 0.88 | AGTR2 (0.46) | AGTR2NR1D1ABHD6DAGLACTSL | |
| SCHEMBL6978115 | 0.88 | AGTR2 (0.46) | AGTR2NR1D1ABHD6DAGLACTSL | |
| SCHEMBL28795618 | 0.84 | POLB (0.43) | AGTR2NR1D1POLBOPRM1OPRD1 | |
| SCHEMBL30207229 | 0.84 | POLB (0.43) | AGTR2NR1D1POLBOPRM1OPRD1 | |
| SCHEMBL8061462 | 0.84 | POLB (0.43) | AGTR2NR1D1POLBOPRM1OPRD1 | |
| SCHEMBL30181418 | 0.84 | POLB (0.43) | AGTR2NR1D1POLBOPRM1OPRD1 | |
| SCHEMBL22555092 | 0.82 | AGTR2 (0.48) | AGTR2NR1D1ABHD6DAGLACTSL | |
| SCHEMBL13662029 | 0.81 | TSHR (0.42) | AGTR2NR1D1CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264431-A1 | NOVEL CATHEPSIN C INHIBITORS AND THEIR USE | CTSB, CTSS, CTSF | AGTR2 463/4885NR1D1 1663/4885POLB 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.